Étiquette : effets indésirables

Study finds no evidence marijuana use increases stroke risk, HealthDay News, 2020.

Study finds no evidence marijuana use increases stroke risk HealthDay News, 2020. https://www.upi.com/Health_News/2020/06/04/Study-finds-no-evidence-marijuana-use-increases-stroke-risk/3321591274273/?upi_ss=Cannabis An observational study conducted at hospitals found no evidence that marijuana use increases risk for stroke. File Photo by Atomazul/Shutterstock Whether pot use increases the risk of stroke has been hotly debated, and now a new study adds to evidence that it doesn't. "Our observational study looked specifically at recent cannabis use by reviewing drug testing data for people admitted to the hospital. While more research is needed with larger numbers of people, our study lends support to the studies showing that cannabis use does not increase the risk of stroke," said [...]

Lire la suite

Cannabidiol Adverse Effects and Toxicity, Marilyn A. Huestis et al., 2019

Cannabidiol Adverse Effects and Toxicity Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier and Francesco Paolo Busardò Current Neuropharmacology, 2019, 17, 974-989 Doi : 10.2174/1570159XI7666190603171901 Abstract : Background : Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. Multiple preclinical and clinical studies led to FDA-approval of Epidiolex®, a purified CBD medicine formulated for oral administration for the treatment of infantile refractory epileptic syndromes, by the US Food and Drug Administration in 2018. The World [...]

Lire la suite

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain, Marta Vázquez et al., 2020,

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain Marta Vázquez, Natalia Guevara, Cecilia Maldonado, Paulo Cáceres Guido, and Paula Schaiquevich Hindawi, BioMed Research International, 2020, Article ID 3902740, 9 pages Doi : 10.1155/2020/3902740 Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between [...]

Lire la suite

Les interactions CBD / médicaments, Swiss Medical Cannabis, 2020

Les interactions CBD / médicaments Posté le 6 avril 2020 par Swiss Medical Cannabis   Depuis l’augmentation de sa demande, le cannabidiol (CBD) attire significativement l’attention sur son potentiel à soulager les symptômes de l’insomnie, de l’anxiété, de la douleur chronique et d’une foule d’autres problèmes de santé. Les recherches menées à ce jour démontrent progressivement que le CBD est d’une grande sécurité d’emploi même à forte dose et peu d’effets secondaires, somme toute mineurs. Toutefois, il existe une mise en garde : le CBD peut interagir avec certains médicaments. L’interrogation porte ainsi sur la façon dont le corps métabolise certaines substances. Avant de [...]

Lire la suite

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial, Elizabeth A. Thiele et al., 2020

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607   IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]

Lire la suite

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients, Diana M. Martinez, MD Medscape .com, 2020

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]

Lire la suite

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington, Jeremy Mennis, Gerald J Stahler, 2020

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]

Lire la suite

A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers, Daniel Perkins et al., 2020

A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers Daniel Perkins · Juliet Butler · Katherine Ong · Tri‑Hung Nguyen · Susan Cox · Barbara Francis · Michelle Mcintosh · Brian Lilley European Journal of Drug Metabolism and Pharmacokinetics, 2020, Doi : 10.1007/s13318-020-00624-6 Abstract Background : There is increasing interest in the use of purified cannabidiol (CBD) as a treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic, antiemetic and anticonvulsant properties. Objective : The objective of this study was to assess the [...]

Lire la suite

The Reemergence of Ketamine for Treatment in Critically Ill Adults, Kimberly P. Hurth et al., 2020

The Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth,  Kristen B. Thomas,  Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335   Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]

Lire la suite

Smoking weed and coronavirus : Even occasional use raises risk of Covid-19 complications, Sandee LaMotte, CNN, avril 2020

Smoking weed and coronavirus : Even occasional use raises risk of Covid-19 complications By Sandee LaMotte, CNN Updated 1222 GMT (2022 HKT) April 10, 2020 (CNN)If you're smoking weed to ease your stress during the coronavirus pandemic, experts say it's time to think twice. Smoking marijuana, even occasionally, can increase your risk for more severe complications from Covid-19, the disease caused by the novel coronavirus. Coronavirus symptoms: 10 key indicators and what to do "What happens to your airways when you smoke cannabis is that it causes some degree of inflammation, very similar to bronchitis, very similar to the type of inflammation that cigarette [...]

Lire la suite